NOVEL APPROACHES IN THE PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS
Abstract
Rheumatoid arthritis is an autoimmune disease, a chronic inflammatory disease that affects more than the joints. There is currently no cure for rheumatoid arthritis, but remarkable progress has been made over the last two decades in therapeutic regimens, with the possibility of long-lasting remission and in particular, prevention of sequelae (joint deformities, ankylosis, reduced mobility and functional capacity). Various drugs are used in the pharmacological treatment: nonsteroidal anti-inflammatory drugs, corticoids, disease-modifying anti-rheumatic drugs, biological agents (acting on the immune system, reducing its erratic activity, with maximum efficacy combined with disease-modifying anti-rheumatic drugs).
References
1. Prakken B, Albani S, Martini A, Juvenile idiopathic arthritis. Lancet 2011; 377(9783): 2138-2149.
2. Shah A, St. Clair EW. Rheumatoid Arthritis. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jame-son JL, Loscalzo J, Eds. Harrison's Principles of Internal Medicine. 19th edition New York, NY: McGraw-Hill Education, 2016.
3. Potter C, Eyre S, Cope A et al., Investigation of association between the TRAF family genes and RA susceptibility. Ann Rheum Dis 2007; 66(10): 1322-1326.
4. Carlens C, Hergens MP, Grunewald J, et al. Smoking, use of moist snuff, and risk of chronic inflam-matory diseases. Am J Respir Crit Care Med 2010; 181(11): 1217-1222.
5. Martin-Trujillo A, van Rietschoten JG, Timmer TC, et al. Loss of imprinting of IGF2 characterizes high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis. Ann Rheum Dis 2010; 69(6): 1239-42.
6. Ha YJ, Lee YJ, Kang EH, Lung involvements in rheumatic diseases: update on the epidemiology, pathogenesis, clinical features, and treatment. Biomed Res Int 2018; 2018: 6930297.
7. Yunt ZX, Solomon JJ, Lung disease in rheumatoid arthritis, Rheum Dis Clin North Am 2015; 41(2): 225-236.
8. Atzeni F, Boiardi L, Sallì S, Benucci M, Sarzi-Puttini P. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev Clin Immunol 2913; 9(7): 649-657.
9. Hoes JN, Jacobs JW, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010; 6(12): 693-702.
10. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2007; 66 Suppl 3: iii2-22.
11. Britsemmer K, Ursum J, Gerritsen M, et al. Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria. Ann Rheum Dis 2011; 70(8): 1468-1470.
12. Callhoff J, Weiss A, Zink A, et al. Impact of biologic therapy on functional status in patients with rheumatoid arthritis - a meta-analysis. Rheumatology (Oxford) 2013; 52(12): 2127-2135.
13. Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 2013; 72(6): 858-862.
14. Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken) 2011; 63(5): 711-720.
15. Chadwick L, Zhao S, Mysler E, Moots RJ, Review of biosimilar trials and data on etanercept in rheumatoid arthritis. Curr Rheumatol Rep 2018; 20(12): 84.
16. https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf
17. Donahue KE, Gartlehner G, Schulman ER, et al. Drug therapy for early rheumatoid arthritis: a sys-tematic review update [Internet], Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jul. Report No.: 18-EHC015-EF.AHRQ Comparative Effectiveness Reviews.
18. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomized, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014; 73(1): 69-74.
19. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009; 68(7): 1094-1099.
20. van der Heijde D, Tanaka Y, Fleischmann R, et al. ORAL Scan Investigators. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65(3): 559-570.
21. Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol 2018; 9: 1157.
22. Weinblatt ME, Bingham CO 3rd, Mendelsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomized, multicenter, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 2013; 72(3): 381-389.
23. Genovese MC, Schiff M, Luggen M, et al. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 2012; 39(8): 1546-1554.
24. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72(12): 1947-1955.
25. De Winter L, Hansen W, Geusens P, et al. New autoantibodies as biomarkers for early and seronega-tive rheumatoid arthritis [abstract OP0181]. Presented at: EULAR 2013, the Annual Congress of the European League Against Rheumatism; Madrid, Spain; June 14, 2013. Ann Rheum Dis 2013; 72(suppl 3): 114.
26. Myasoedova E, Crowson CS, Nicola PJ, et al. The influence of rheumatoid arthritis disease character-istics on heart failure. J Rheumatol 2011; 38(8): 1601-1606.
27. Fleischmann R, Kremer J, Cush J et al. Placebo-controlled trial of tofacitinib monotherapy in rheuma-toid arthritis. N Engl J Med 2012; 367(6): 495-507.
28. Rang HP, Ritter JM, Flower RJ, et al., Rang and Dale’s Pharmacology, 8th edition, Elsevier Churchill Livingstone, 2016, Chapter 26: Anti-inflammatory and imunosupressant drugs, 626-641.
29. DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy: A Pathophysiologic Approach, 10th edition, Mc Graw Hill Education USA, 2017, Chapter 91: Rheumatoid Arthritis, 4034-4075.
30. Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 2012b; 24(3): 335-341.
31. Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of inter-leukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other in-flammatory conditions. Ann Rheum Dis 2013; 72(4): 482-492.
32. Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010; 363(14): 1303-1312.
2. Shah A, St. Clair EW. Rheumatoid Arthritis. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jame-son JL, Loscalzo J, Eds. Harrison's Principles of Internal Medicine. 19th edition New York, NY: McGraw-Hill Education, 2016.
3. Potter C, Eyre S, Cope A et al., Investigation of association between the TRAF family genes and RA susceptibility. Ann Rheum Dis 2007; 66(10): 1322-1326.
4. Carlens C, Hergens MP, Grunewald J, et al. Smoking, use of moist snuff, and risk of chronic inflam-matory diseases. Am J Respir Crit Care Med 2010; 181(11): 1217-1222.
5. Martin-Trujillo A, van Rietschoten JG, Timmer TC, et al. Loss of imprinting of IGF2 characterizes high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis. Ann Rheum Dis 2010; 69(6): 1239-42.
6. Ha YJ, Lee YJ, Kang EH, Lung involvements in rheumatic diseases: update on the epidemiology, pathogenesis, clinical features, and treatment. Biomed Res Int 2018; 2018: 6930297.
7. Yunt ZX, Solomon JJ, Lung disease in rheumatoid arthritis, Rheum Dis Clin North Am 2015; 41(2): 225-236.
8. Atzeni F, Boiardi L, Sallì S, Benucci M, Sarzi-Puttini P. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev Clin Immunol 2913; 9(7): 649-657.
9. Hoes JN, Jacobs JW, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010; 6(12): 693-702.
10. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2007; 66 Suppl 3: iii2-22.
11. Britsemmer K, Ursum J, Gerritsen M, et al. Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria. Ann Rheum Dis 2011; 70(8): 1468-1470.
12. Callhoff J, Weiss A, Zink A, et al. Impact of biologic therapy on functional status in patients with rheumatoid arthritis - a meta-analysis. Rheumatology (Oxford) 2013; 52(12): 2127-2135.
13. Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 2013; 72(6): 858-862.
14. Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken) 2011; 63(5): 711-720.
15. Chadwick L, Zhao S, Mysler E, Moots RJ, Review of biosimilar trials and data on etanercept in rheumatoid arthritis. Curr Rheumatol Rep 2018; 20(12): 84.
16. https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf
17. Donahue KE, Gartlehner G, Schulman ER, et al. Drug therapy for early rheumatoid arthritis: a sys-tematic review update [Internet], Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jul. Report No.: 18-EHC015-EF.AHRQ Comparative Effectiveness Reviews.
18. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomized, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014; 73(1): 69-74.
19. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009; 68(7): 1094-1099.
20. van der Heijde D, Tanaka Y, Fleischmann R, et al. ORAL Scan Investigators. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65(3): 559-570.
21. Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol 2018; 9: 1157.
22. Weinblatt ME, Bingham CO 3rd, Mendelsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomized, multicenter, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 2013; 72(3): 381-389.
23. Genovese MC, Schiff M, Luggen M, et al. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 2012; 39(8): 1546-1554.
24. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72(12): 1947-1955.
25. De Winter L, Hansen W, Geusens P, et al. New autoantibodies as biomarkers for early and seronega-tive rheumatoid arthritis [abstract OP0181]. Presented at: EULAR 2013, the Annual Congress of the European League Against Rheumatism; Madrid, Spain; June 14, 2013. Ann Rheum Dis 2013; 72(suppl 3): 114.
26. Myasoedova E, Crowson CS, Nicola PJ, et al. The influence of rheumatoid arthritis disease character-istics on heart failure. J Rheumatol 2011; 38(8): 1601-1606.
27. Fleischmann R, Kremer J, Cush J et al. Placebo-controlled trial of tofacitinib monotherapy in rheuma-toid arthritis. N Engl J Med 2012; 367(6): 495-507.
28. Rang HP, Ritter JM, Flower RJ, et al., Rang and Dale’s Pharmacology, 8th edition, Elsevier Churchill Livingstone, 2016, Chapter 26: Anti-inflammatory and imunosupressant drugs, 626-641.
29. DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy: A Pathophysiologic Approach, 10th edition, Mc Graw Hill Education USA, 2017, Chapter 91: Rheumatoid Arthritis, 4034-4075.
30. Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 2012b; 24(3): 335-341.
31. Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of inter-leukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other in-flammatory conditions. Ann Rheum Dis 2013; 72(4): 482-492.
32. Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010; 363(14): 1303-1312.
Published
2019-12-29
Section
PHARMACY
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
